Sachin A. Gupte, M.D., Ph.D.
Sachin Gupte, M.D., Ph.D., has more than 25 years of education in medicine and the basic sciences. His formal training in cardiovascular medicine and vascular physiology/biology as well as his expertise in redox signaling have prepared him to generate novel hypotheses with immediate translational relevance and to motivate, instruct, and graduate students and fellows. Dr. Gupte has trained more than 29 graduate students and post-doctoral fellows who have successfully pursued careers in research, academia, the pharma industry and/or clinical practice.
Education
- Ph.D., Physiology, Juntendo University School of Medicine
Research
The focus of the ongoing studies in Dr. Gupte's laboratory is elucidating the role of glucose-6-phosphate dehydrogenase-derived NADPH in regulating vascular function (mechanics) and the vessel wall structure. In that context, the lab studies regulation of epigenomic (genes) and phenomic modifications of vascular smooth muscle cell by glucose-6-phosphate dehydrogenase-dependent redox signaling in a variety of in vitro and in vivo systems using state-of-the-art tools in next generation sequencing, molecular biology, and physiology. Another major project that his lab is involved in is to model the human G6PD variants in cell culture and animal models using the revolutionary CRISPR-Cas9 system of genome editing to study their role in regulation of cardiovascular function. At present, his lab is actively elucidating the cellular mechanism(s) through which glucose-6-phosphate dehydrogenase-dependent pyridine nucleotide signaling regulate vascular smooth muscle cell phenotype in normal and disease conditions such as pulmonary hypertension (PH), metabolic syndrome-associated coronary artery disease (MS-CAD) and heart failure.
Particularly, Dr. Gupte's lab is examining the role of pyridine nucleotide signaling in regulating extracellular matrix remodeling and autophagic or apoptotic death of cardiomyocytes during the development of PAH and MS-CAD. Overall, the aim will be to study the metabolic adaptation-cardiovascular function relationship using biochemical, molecular, pharmacological and genetic approaches in novel animal models and in vitro systems that mimic human diseases and to explore novel therapies for PAH and MS-CAD.
Publications
- Signoretti C, Matsumura S, Fatehi S, et. al. "G6pd(N126D) Variant Increases the Risk of Developing VEGFR (Vascular Endothelial Growth Factor Receptor) Blocker-Induced Pulmonary Vascular Disease." Journal of the American Heart Association, (), (2024) e035174. doi: 10.1161/JAHA.123.035174
- Matsumura S, Signoretti C, Fatehi S, et. al. "Loss-of-function G6PD variant moderated high-fat diet-induced obesity, adipocyte hypertrophy, and fatty liver in male rats." The Journal of biological chemistry, 300(7), (2024) 107460. doi: 10.1016/j.jbc.2024.107460
- Signoretti C, Gupte SA. "G6PD Orchestrates Genome-Wide DNA Methylation and Gene Expression in the Vascular Wall." International journal of molecular sciences, 24(23), (2023) . doi: 10.3390/ijms242316727
- Krajnik A, Nimmer E, Brazzo JA 3rd, et. al. "Survivin regulates intracellular stiffness and extracellular matrix production in vascular smooth muscle cells." APL bioengineering, 7(4), (2023) 046104. doi: 10.1063/5.0157549
- D'Addario CA, Matsumura S, Kitagawa A, et. al. "Global and endothelial G-protein coupled receptor 75 (GPR75) knockout relaxes pulmonary artery and mitigates hypoxia-induced pulmonary hypertension." Vascular pharmacology, 153(), (2023) 107235. doi: 10.1016/j.vph.2023.107235
- Gupte SA, Bakshi CS, Blackham E, et. al. "The severity of SARS-CoV-2 infection in K18-hACE2 mice is attenuated by a novel steroid-derivative in a gender-specific manner." British journal of pharmacology, 180(20), (2023) 2677-2693. doi: 10.1111/bph.16155
- Signoretti C, Gupte SA. "Studies in CRISPR-generated Mediterranean G6PD variant rats reveal G6PD orchestrates genome-wide DNA methylation and gene expression in vascular wall." bioRxiv : the preprint server for biology, (), (2023) . pii: 2023.03.06.531429. doi: 10.1101/2023.03.06.531429
Recent Presentations
- CRISPR-Cas9 editing in rats reveal the role of G6PD and NADPH redox in regulating epigenetics of VSMC and vascular biology, Augusta University, GA, United States of America. (08/2020).
- G6PD and Vascular Diseases, University of Rochester, NY, United States of America. (01/2019).
- G6PD and Pulmonary Hypertension, University of Colorado Health Science Center, CO, United States of America. (04/2018).
- Cyp2c44: Stem Cells and Vascular Inflammation/Pathology, The 17th International Winter Eicosanoid Conference, MD, March 11-13, 2018.
Professional Service
Peer Review (Journal Review):
- 2018-Present Journal of Vascular Research
- 2018-Present Vascular Pharmacology
- 2017-Present Hypertension
- 2011-Present FEBS letter
- 2011-Present Tumor Biology
- 2011-Present Biochmie
- 2011-Present Food and Chemical Toxicology
- 2009-Present Free Radical Biology & Medicine
- 2009-Present BBA
- 2008-Present Antioxidant & Redox Signaling
- 2008-Present JBC
- 2007-Present Diabetes; Diabetologia
- 2007-Present Annals of Thoracic Surgery
- 2006-Present European Journal of Pharmacology
- 2006-Present Biochemical Pharmacology
- 2005-Present FASEB Journal
- 2005-Present Experimental Cell Medicine
- 2005-Present Journal of American Society of Nephrology
- 2004-Present American Journal of Hypertension
- 2004-Present Journal of Molecular and Cellular Cardiology
- 2004-Present Journal of Post Graduate Medicine
- 2002-Present American Journal of Physiology (Heart & Circulation)
Memberships and Affiliations
- Editorial Board Member, American Journal of Physiology (Heart and Circulation), 2005-2020
- Ad hoc member, French Health Ministry, Review Committee, 2019
Teaching Responsibilities
- Cardiovascular and Respiratory Pharmacology/Medicine
